Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEJNJ-70218902Cat.No.:HY-P991172作?靶點:CD3;TransmembraneGlycoprotein作?通路:Immunology/Inflammation儲存?式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY?物活性JNJ-70218902?種雙特異性抗體，可與表達TMEFF2的腫瘤細胞和T細胞上的CD3結合。JNJ-70218902引起露依賴性促炎反應和靶向腫瘤細胞裂解，并促進T細胞介導的腫瘤細胞殺滅(EC50:1.4nM)。JNJ-70218902對于前列腺癌的研究具有豐富的潛?。推薦同型對照為?IgG4kappa，同型對照(HY-P99003)[1]。體外研究JNJ-70218902bindstoTMEFF2-positiveLNCaP-ARcells(EC50:9.6nM)butnottoTMEFF2-negativeDU145prostatecancercells[1].JNJ-70218902hasahighbindingaffinityforCD3onprimaryhumanTcells(KD:151nM)[1].JNJ-70218902inducesTcell-mediatedkilling(EC50:1.4nM)whenincubateswithhealthyhumandonorTcellsandLNCaP-ARcellsataneffector-targetratioof3:1,andTcellactivationisdemonstratedbyincreasedcellsurfaceCD8+CD25+expressionandpro-inflammatorycytokines[1].JNJ-70218902showslowcytotoxicityinDU145cells[1].體內研究JNJ-70218902hasantitumoractivityatincreasingconcentrationsupto5mg/kginTcellhumanizedNSGmicebearingLNCaPxenografts(tumorgrowthinhibitionratesof75-122%)andLuCaP86.2patient-derivedxenografts(tumorgrowthinhibitionratesof72-88%)[1].JNJ-70218902(0.075mg/kgor0.075mg/kg,then0.3mg/kgafteroneweek)inacynomolgusmonkeymodelofprostatecancercaninducetheinfiltrationofactivatedandproliferatingTcellsandinflammatorycellsintotheprostate,mediatinganeffectiveimmuneresponse[2].REFERENCES[1].BasuSetal.AbstractLB087:CharacterizationofJNJ-70218902,aTMEFF2xCD3bispecificantibody,inprostatecancermodels1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemECancerResearch82.12_Supplement(2022):LB087-LB087.[2].LowensteinC,etal.1360PharmacodynamicsofJNJ-70218902,aTMEFF2×CD3bispecificantibody,incynomolgusmonkey.(2022).McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400